Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Retinal Microvascular Changes Do Not Appear to Predict 90-Day Risk of Stroke and Cardiovascular Events (CVE) among Patients Presenting to the Emergency Department with Suspected TIA: The FOTO-TIA Study
Cerebrovascular Disease and Interventional Neurology
Cerebrovascular Disease and Interventional Neurology Posters (7:00 AM-5:00 PM)
149

A primary aim of the study was to investigate whether retinal microvascular findings in patients with suspected TIA helped to predict their risk of stroke or CVE within 90 days.

About 10% of the 250–500,000 Americans who experience TIA annually have a stroke within 90 days.

We undertook a cohort study of adult patients with a NIH Stroke Scale ≤ 3 admitted to three emergency departments’ (EDs’) observation units for an accelerated diagnostic protocol for suspected TIA or stroke. Clinical and imaging results were recorded prospectively. Non-mydriatic fundus photographs were obtained as part of the accelerated diagnostic protocol and reviewed for retinal microvascular findings, defined as retinal hemorrhages, cotton wool spots, retinal emboli or occlusions, hard exudates, or microaneurysms. Stroke and CVE were adjudicated by a stroke neurologist.

Among the 395 patients enrolled (median age: 57 years (interquartile range [IQR]: 50–66); 219 (55%) women; 253 (64%) black; 34 (9%) retinal microvascular findings present), 154 (39%) completed 90-day follow-up visits.  Within 90 days, 3/395 (0.8%) had a stroke, 3 additional subjects had a recurrent TIA, and none had a CVE.  All patients with a stroke or recurrent TIA had an ABCD2 score >3 vs. 70% (273/295; p=0.25) of other patients, and none had any microvascular findings vs. 9% (34/392; p=0.59) of other patients.

Although we have found that retinal microvascular findings among patients with suspected TIA in the ED are an independent factor differentiating TIA and stroke from mimics, our study is unable to provide evidence that they improve short-term predictions of future ischemic events.  However, our study was underpowered due to a much lower occurrence of short-term stroke than expected at the time of its design, likely due in large part to improved secondary prevention, in particular, from the type of accelerated diagnostic protocol our patients underwent.

Authors/Disclosures
Beau B. Bruce, MD, FÂé¶¹´«Ã½Ó³»­ (Centers for Disease Control & Prevention)
PRESENTER
Dr. Bruce has received personal compensation in the range of $50,000-$99,999 for serving as an Expert Witness for Bayer.
No disclosure on file
Fadi B. Nahab, MD Dr. Nahab has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Legal Consultation. Dr. Nahab has received intellectual property interests from a discovery or technology relating to health care.
No disclosure on file
No disclosure on file
No disclosure on file
Benjamin Meyer Mr. Meyer has nothing to disclose.
No disclosure on file
No disclosure on file
Valerie Biousse, MD Dr. Biousse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Gensights Biologic. Dr. Biousse has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Topcon. Dr. Biousse has received publishing royalties from a publication relating to health care. Dr. Biousse has received publishing royalties from a publication relating to health care.
Nancy J. Newman, MD, FÂé¶¹´«Ã½Ó³»­ (Emory University School of Medicine) Dr. Newman has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for GenSight. Dr. Newman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Chiesi. Dr. Newman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Stoke. Dr. Newman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Newman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Phelcom. The institution of Dr. Newman has received research support from GenSight. Dr. Newman has received publishing royalties from a publication relating to health care. Dr. Newman has received publishing royalties from a publication relating to health care. Dr. Newman has received publishing royalties from a publication relating to health care.